As A Botanical, Cannabidiol Was Next Ingredient Up For AHPA's Guidance On Use In Supplements
Leading discussions on CBD safety as a dietary ingredient and developing best-practices guidance were natural steps for AHPA. "We were viewing it as another botanical product, another one of the type of products that we’ve been dealing with throughout our history," said program development director Jane Wilson.
You may also be interested in...
FDA schedules public meeting for 19 November to discuss sex and gender differences in the use and response to cannabidiols. The meeting will address the issue of CBD use in pregnancy, for which no human data currently is available.
In report to Congress about determining an enforcement discretion policy for CBD-containing non-drug products, FDA described challenges it faces, largely unique in its history, in determining whether hemp-derived ingredients are safe in food, supplements and other products that already are “sold increasingly widely."
There's a reason the FDA continues accepting comments on questions about using hemp- and cannabis-derived ingredients in products other than drugs months after the comment period closed. "It's safe to say say that in 4,500 comments, we did not receive a lot of hard data around the issues that we specifically requested comments on," says Sharon Mayl, senior advisor for policy in the commissioner's office.